Last reviewed · How we verify

Hu3F8 — Competitive Intelligence Brief

Hu3F8 (NAXITAMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycolipid Disialoganglioside-directed Antibody [EPC]. Area: Oncology.

marketed Glycolipid Disialoganglioside-directed Antibody [EPC] Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Hu3F8 (NAXITAMAB) — Y-Mabs Therapeutics Inc. Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hu3F8 TARGET NAXITAMAB Y-Mabs Therapeutics Inc marketed Glycolipid Disialoganglioside-directed Antibody [EPC] 2020-01-01
Ch14.18 DINUTUXIMAB United Therap marketed Glycolipid Disialoganglioside-directed Antibody [EPC] GD2 2015-01-01
DANYELZA NAXITAMAB-GQGK Y-MABS THERAPEUTICS INC marketed Glycolipid Disialoganglioside-directed Antibody [EPC] GD2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycolipid Disialoganglioside-directed Antibody [EPC] class)

  1. United Therap · 1 drug in this class
  2. Y-MABS THERAPEUTICS INC · 1 drug in this class
  3. Y-Mabs Therapeutics Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hu3F8 — Competitive Intelligence Brief. https://druglandscape.com/ci/naxitamab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: